Literature DB >> 31756109

Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.

Sumanta Garai1, Pushkar M Kulkarni1, Peter C Schaffer1, Luciana M Leo2, Asher L Brandt3, Ayat Zagzoog3, Tallan Black3, Xiaoyan Lin4, Dow P Hurst5, David R Janero6, Mary E Abood2, Anaelle Zimmowitch4, Alex Straiker4, Roger G Pertwee7, Melanie Kelly8, Anna-Maria Szczesniak8, Eileen M Denovan-Wright8, Ken Mackie4, Andrea G Hohmann4, Patricia H Reggio5, Robert B Laprairie3,8, Ganesh A Thakur1.   

Abstract

Cannabinoid 1 receptor (CB1R) allosteric ligands hold a far-reaching therapeutic promise. We report the application of fluoro- and nitrogen-walk approaches to enhance the drug-like properties of GAT211, a prototype CB1R allosteric agonist-positive allosteric modulator (ago-PAM). Several analogs exhibited improved functional potency (cAMP, β-arrestin 2), metabolic stability, and aqueous solubility. Two key analogs, GAT591 (6r) and GAT593 (6s), exhibited augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55,940). Both analogs also exhibited good analgesic potency in the CFA inflammatory-pain model with longer duration of action over GAT211 while being devoid of adverse cannabimimetic effects. Another analog, GAT592 (9j), exhibited moderate ago-PAM potency and improved aqueous solubility with therapeutic reduction of intraocular pressure in murine glaucoma models. The SAR findings and the enhanced allosteric activity in this class of allosteric modulators were accounted for in our recently developed computational model for CB1R allosteric activation and positive allosteric modulation.

Entities:  

Year:  2020        PMID: 31756109     DOI: 10.1021/acs.jmedchem.9b01142

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.

Authors:  Dan L McElroy; Andrew J Roebuck; Gavin A Scott; Quentin Greba; Sumanta Garai; Eileen M Denovan-Wright; Ganesh A Thakur; Robert B Laprairie; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2021-01-13       Impact factor: 4.530

2.  The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Peter T Doohan; Nicole A Hawkins; Dilara Bahceci; Sumanta Garai; Ganesh A Thakur; Jennifer A Kearney; Jonathon C Arnold
Journal:  Neuropharmacology       Date:  2021-11-22       Impact factor: 5.273

3.  Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.

Authors:  Ayat Zagzoog; Asher L Brandt; Tallan Black; Eunhyun D Kim; Riley Burkart; Mikin Patel; Zhiyun Jin; Maria Nikolaeva; Robert B Laprairie
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

4.  Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.

Authors:  Hongguang Ma; Huiqun Wang; James C Gillespie; Rolando E Mendez; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2021-03-22       Impact factor: 2.940

5.  In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.

Authors:  Ayat Zagzoog; Kawthar A Mohamed; Hye Ji J Kim; Eunhyun D Kim; Connor S Frank; Tallan Black; Pramodkumar D Jadhav; Larry A Holbrook; Robert B Laprairie
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

6.  The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.

Authors:  Dan L McElroy; Andrew J Roebuck; Quentin Greba; Sumanta Garai; Asher L Brandt; Orhan Yilmaz; Stuart M Cain; Terrance P Snutch; Ganesh A Thakur; Robert B Laprairie; John G Howland
Journal:  IBRO Neurosci Rep       Date:  2022-01-24

Review 7.  Novel approaches and current challenges with targeting the endocannabinoid system.

Authors:  Paula Morales; Nadine Jagerovic
Journal:  Expert Opin Drug Discov       Date:  2020-04-27       Impact factor: 7.050

8.  Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6.

Authors:  Jean Jacques Vanden Eynde; Arduino A Mangoni; Jarkko Rautio; Jérôme Leprince; Yasu-Taka Azuma; Alfonso T García-Sosa; Christopher Hulme; Josef Jampilek; Rafik Karaman; Wei Li; Paula A C Gomes; Dimitra Hadjipavlou-Litina; Raffaele Capasso; Athina Geronikaki; Laura Cerchia; Jean-Marc Sabatier; Rino Ragno; Tiziano Tuccinardi; Andrea Trabocchi; Jean-Yves Winum; F Javier Luque; Katalin Prokai-Tatrai; Mariana Spetea; Michael Gütschow; Ivan Kosalec; Catherine Guillou; M Helena Vasconcelos; George Kokotos; Giulio Rastelli; Maria Emília de Sousa; Clementina Manera; Sandra Gemma; Stefano Mangani; Carlo Siciliano; Stefania Galdiero; Hong Liu; Peter J H Scott; Cristóbal de Los Ríos; Luigi A Agrofoglio; Simona Collina; Rita C Guedes; Diego Muñoz-Torrero
Journal:  Molecules       Date:  2019-12-28       Impact factor: 4.411

9.  Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward.

Authors:  Richard A Slivicki; Vishakh Iyer; Sonali S Mali; Sumanta Garai; Ganesh A Thakur; Jonathon D Crystal; Andrea G Hohmann
Journal:  Front Mol Neurosci       Date:  2020-04-28       Impact factor: 5.639

Review 10.  CB1 Cannabinoid Receptor Signaling and Biased Signaling.

Authors:  Luciana M Leo; Mary E Abood
Journal:  Molecules       Date:  2021-09-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.